© 2018 Société Française du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés.
Publication types
-
Editorial
-
Introductory Journal Article
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological / therapeutic use
-
B7-H1 Antigen / antagonists & inhibitors
-
B7-H1 Antigen / immunology
-
CTLA-4 Antigen / antagonists & inhibitors
-
CTLA-4 Antigen / immunology
-
Humans
-
Immunologic Surveillance
-
Immunotherapy / methods*
-
Ipilimumab / therapeutic use
-
Neoplasms / therapy*
-
Nobel Prize
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / immunology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
B7-H1 Antigen
-
CD274 protein, human
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
tremelimumab